Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference

Europace

Volumn 15, Issue 11, 2013, Pages 1540-1556

  Kirchhof, Paulus ^a,b,c   Breithardt, Günter ^b,c   Aliot, Etienne ^d   Al Khatib, Sana ^e   Apostolakis, Stavros ^a   Auricchio, Angelo ^f   Bailleul, Christophe ^g   Bax, Jeroen ^h   Benninger, Gerlinde ^b,c   Blomstrom Lundqvist, Carina ⁱ   Boersma, Lucas ^j   Boriani, Giuseppe ^k   Brandes, Axel ^l   Brown, Helen ^m   Brueckmann, Martina ^n,o   Calkins, Hugh ^p   Casadei, Barbara ^q   Clemens, Andreas ^o   Crijns, Harry ^r   Derwand, Roland ^s   Dobrev, Dobromir ^t   Ezekowitz, Michael ^u   Fetsch, Thomas ^v   Gerth, Andrea ^w   Gillis, Anne ^x   Gulizia, Michele ^y   Hack, Guido ^z   Haegeli, Laurent ^aa   Hatem, Stephane ^ab   Georg Häusler, Karl ^c,ac   Heidbüchel, Hein ^ad   Hernandez Brichis, Jessica ^s   Jais, Pierre ^ae   Kappenberger, Lukas ^af   Kautzner, Joseph ^ag   Kim, Steven ^g   Kuck, Karl Heinz ^ah   Lane, Deirdre ^a   Leute, Angelika ^b,c   Lewalter, Thorsten ^c,ai   Meyer, Ralf ^aj   Mont, Lluis ^ak   Moses, Gregory ^l   Mueller, Markus ^al   Münzel, Felix ^s   Näbauer, Michael ^c,w   Nielsen, Jens Cosedis ^am   Oeff, Michael ^c,an   Oto, Ali ^ao   Pieske, Burkert ^ap   Pisters, Ron ^r   Potpara, Tatjana ^aq   Rasmussen, Lars ^am   Ravens, Ursula ^c,ar   Reiffel, James ^as   Richard Lordereau, Isabelle ^z   Schäfer, Herbert ^at   Schotten, Ulrich ^c,r   Stegink, Wim ^au   Stein, Kenneth ^av   Steinbeck, Gerhard ^c,aw   Szumowski, Lukasz ^ax   Tavazzi, Luigi ^ay   Themistoclakis, Sakis ^az   Thomitzek, Karen ^ba   Van Gelder, Isabelle C ^bb   Von Stritzky, Berndt ^bc   Vincent, Alphons ^aj   Werring, David ^bd   Willems, Stephan ^be   Lip, Gregory Y H ^a   John Camm, A ^bf   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c AFNET   (Germany)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DIVISION OF CARDIOLOGY   (Switzerland)

^g St Jude Medical Inc USA   (United States)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UPPSALA UNIVERSITY   (Sweden)

^j ST ANTONIUS HOSPITAL   (Netherlands)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l ODENSE UNIVERSITY HOSPITAL   (Denmark)

^m Meda Pharma   (France)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^p JOHNS HOPKINS HOSPITAL   (United States)

^q UNIVERSITY OF OXFORD   (United Kingdom)

^r MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^s DAIICHI SANKYO CO   (Japan)

^t UNIVERSITY OF DUISBURG ESSEN   (Germany)

^u LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^v CRI The Clinical Research Institute   (Germany)

^w UNIVERSITY OF MUNICH   (Germany)

^x UNIVERSITY OF CALGARY   (Canada)

^y Garibaldi Nesima Hospital   (Italy)

^z BRISTOL MYERS SQUIBB   (United States)

^aa UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^ab PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^ac CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^ad UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ae UNIVERSITÉ DE BORDEAUX   (France)

^af UNIVERSITY OF LAUSANNE   (Switzerland)

^ag INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^ah DEPARTMENT OF CARDIOLOGY   (Germany)

^ai Isar Herzzentrum   (Germany)

^aj Tolochenaz   (Switzerland)

^ak UNIVERSITY OF BARCELONA   (Spain)

^al PFIZER INC   (United States)

^am AARHUS UNIVERSITY HOSPITAL   (Denmark)

^an Klinikum Brandenburg   (Germany)

^ao HACETTEPE UNIVERSITY   (Turkey)

^ap MEDICAL UNIVERSITY OF GRAZ   (Austria)

^aq UNIVERSITY OF BELGRADE   (Serbia)

^ar DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^as NewYork Presbyterian Hospital   (United States)

^at BAYER AG   (Germany)

^au St Jude Medical   (Belgium)

^av Boston Scientific   (United States)

^aw Zentrum für Kardiologie und Angiologie am Klinikum Starnberg   (Germany)

^ax INSTITUTE OF CARDIOLOGY   (Poland)

^ay Ettore Sansavini Health Science Foundation   (Italy)

^az OSPEDALE DELL'ANGELO   (Italy)

^ba BAYER PHARMA AG   (Germany)

^bb UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^bc SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^bd UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^be UNIVERSITY HEART CENTER HAMBURG   (Germany)

^bf ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

Anticoagulation; Atrial fibrillation; Biomarkers; Electrocardiogram; Genetics; Imaging; Personalised medicine; Rate control; Rhythm control

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CREATININE; UNSATURATED FATTY ACID; RATE CONTROL;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; BLOOD; BRAIN HEMORRHAGE; CARDIAC IMAGING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CREATININE BLOOD LEVEL; DISEASE BURDEN; ELECTROCARDIOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; GENETIC MARKER; GENETIC PREDISPOSITION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INFLAMMATION; NEUROIMAGING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RECURRENT DISEASE; SINUS RHYTHM; VALVULAR HEART DISEASE; WHITE MATTER; ANTICOAGULATION; BRAIN; DISEASE MANAGEMENT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GENETICS; HEART ATRIUM FIBRILLATION; IMAGING; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RHYTHM CONTROL; RISK FACTOR; TREATMENT OUTCOME;

ANTICOAGULATION; ATRIAL FIBRILLATION; BIOMARKERS; ELECTROCARDIOGRAM; GENETICS; IMAGING; PERSONALISED MEDICINE; RATE CONTROL; RHYTHM CONTROL;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BRAIN; DISEASE MANAGEMENT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; RISK FACTORS; TREATMENT OUTCOME;

EID: 84883231774     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut232     Document Type: Conference Paper

References (219)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, ParekhA et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-92.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
4. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41.
5. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
6. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, NataleAet al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: A randomized controlled trial. JAMA 2010;303: 333-40.
7. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.
8. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
9. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B et al.Arandomized active-controlled study comparing the efficacyand safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57: 313-21.
10. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U et al. Shortterm versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012;380:238-46.
11. Savelieva I, Kirchhof P, Danchin N, de Graeff PA, Camm AJ. Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. Europace 2011;13:1063-76.
12. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-9.
13. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: Implications for stroke prevention. Circulation 2013;127:930-7.
14. Ritter MA, Kochhauser S, Duning T, Reinke F, Pott C, Dechering DG et al. Occult atrial fibrillation in cryptogenic stroke: Detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke 2013, published online 3 February 2013.
15. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): A community-based cohort study. Lancet 2009;373:739-45.
16. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev 2011;91:265-325.
17. GudbjartssonDF, ArnarDO,Helgadottir A, Gretarsdottir S,Holm H, SigurdssonA et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-7.
18. Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, ScheldHHet al. PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet 2011;4: 123-33.
19. Wang J, Klysik E, Sood S, Johnson RL, Wehrens XH, Martin JF. Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci USA 2010;107:9753-8.
20. O'Donnell M, OczkowskiW, Fang J, Kearon C, Silva J, Bradley Cet al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: An observational study. Lancet Neurol 2006;5:749-54.
21. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P et al. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST). Am H J 2013; in press.
22. Chen LY, Sotoodehnia N, Buzkova P, Lopez FL, Yee LM, Heckbert SR et al. Atrial fibrillation and the risk of sudden cardiac death: The atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med 2013;173:29-35.
23. Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 2011;305:2080-7.
24. Atzema CL, Austin PC, Chong AS, Dorian P. Factors associated with 90-day death after emergency department discharge for atrial fibrillation. Ann Emerg Med 2013; in press.
25. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA III et al. 2011 ACCF/AHA/HRS focused update on the Management of Patients with Atrial Fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-23.
26. Wann LS, Curtis AB, Ellenbogen KA, EstesNAIII, EzekowitzMD,JackmanWMet al. 2011 ACCF/AHA/HRS focused update on the Management of Patients with Atrial Fibrillation (update on Dabigatran): A report of theAmerican College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:1144-50.
27. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS et al. Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125-36.
28. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
29. Kirchhof P, Curtis AB, Skanes AC, Gillis AM, SamuelWann L, John Camm A. Atrial fibrillation guidelines across the Atlantic: A comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471-4.
30. Lopes RD, Al-Khatib SM,Wallentin L, Yang H, Ansell J, Bahit MC et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial. Lancet 2012;380:1749-58.
31. Friberg L, RosenqvistM, LipGY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish Atrial Fibrillation Cohort Study. Circulation 2012;125:2298-307.
32. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, LipGY.Anovel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100.
33. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49.
34. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
35. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR( 2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012;60:861-7.
36. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation onoutcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4.
37. Moorhouse P, Rockwood K. Frailty and its quantitative clinical evaluation. J R Coll Physicians Edinb 2012;42:333-40.
38. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: A systematic review. Age Ageing 2011;40:675-83.
39. CammAJ, Kirchhof P, LipGY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
40. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e269-367.
41. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9:1006-23.
42. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L et al. Outpatient treatment of recent-onset atrial fibrillation with the 'pill-in-the-pocket' approach.NEngl J Med 2004;351:2384-91.
43. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H et al. Systematic review and meta-Analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-79.
44. Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, MaggioniAP,CammAJ et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: The Euro Heart Survey. Europace 2012;14: 666-74.
45. Kirchhof P, Mönnig G,Wasmer K, Heinecke A, Breithardt G, Eckardt L et al. A trial of self-Adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 2005;26:1292-7.
46. Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac drugs effects: Individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol 2010;106:263-8.
47. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in longQTsyndrome: A systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 2009;54:143-9.
48. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, KongstadOet al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med 2012;367:1587-95.
49. Turakhia MP, Hoang DD, Xu X, Frayne S, Schmitt S, Yang F et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. Am Heart J 2013;165:93-101 e1.
50. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A et al. Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011;105:1010-23.
51. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R et al. Nurse-led care vs. usual care for patients with atrial fibrillation: Results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2013; in press.
52. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, CammAJ et al.Aproposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J 2013; in press.
53. Budeus M, Hennersdorf M, Felix O, Reimert K, Perings C, WienekeH et al. Prediction of atrial fibrillation in patients with cardiac dysfunctions: Pwave signal-Averaged ECG and chemoreflex sensitivity in atrial fibrillation. Europace 2007;9:601-7.
54. Zhang BC, Che WL,LiWM,XuYW. Meta-Analysis of Pwave character as predictor of atrial fibrillation after coronary artery bypass grafting. Int J Cardiol 2011;152: 260-2.
55. Darbar D, Jahangir A, Hammill SC, Gersh BJ. P wave signal-Averaged electrocardiography to identify risk for atrial fibrillation. Pacing Clin Electrophysiol 2002;25: 1447-53.
56. Jordaens L, Tavernier R, Gorgov N, Kindt H, Dimmer C, Clement DL. Signal-Averaged P wave: Predictor of atrial fibrillation. J Cardiovasc Electrophysiol 1998;9:S30-4.
57. Steinbigler P, Haberl R, Konig B, Steinbeck G. P-wave signal averaging identifies patients prone to alcohol-induced paroxysmal atrial fibrillation. Am J Cardiol 2003;91:491-4.
58. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, SantiniMet al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: Follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008;29: 1181-9.
59. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: An ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-61.
60. AhmadY, Kirchhof P.Gonefishing (for silent atrial fibrillation). Circulation 2013;127: 870-2.
61. Lee J, Reyes BA, McManus DD, Mathias O, Chon KH. Atrial fibrillation detection using a smart phone. Conf Proc IEEE Eng Med Biol Soc 2012;2012:1177-80.
62. Binici Z, Intzilakis T, NielsenOW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 2010; 121:1904-11.
63. Chong BH, Pong V, Lam KF, Liu S, Zuo ML, Lau YF et al. Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. Europace 2012;14:942-7.
64. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D et al. Longterm outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009;301:2571-7.
65. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 2009;11:860-85.
66. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRAConsensus Conference. Europace 2012;14:8-27.
67. Ip J,Waldo AL, LipGY, Rothwell PM, MartinDT, BersohnMMet al. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort The IMPACT study. Am Heart J 2009;158:364-70 e1.
68. Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): Design and rationale. Am Heart J 2010;160:36-41 e1.
69. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T et al. Prevention of atrial fibrillation after cardioversion: Results of the PAFAC trial. Eur Heart J 2004; 25:1385-94.
70. Singh BN, Singh SN, Reda DJ,Tang XC, Lopez B, HarrisCL et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72.
71. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987-99.
72. Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, DluzniewskiMet al. Suppression of paroxysmal atrial tachyarrhythmias-results of the SOPAT trial. Eur Heart J 2004; 25:1395-404.
73. de Groot NM, Houben RP, Smeets JL, Boersma E, Schotten U, Schalij MJ et al. Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease. Epicardial breakthrough. Circulation 2013; in press.
74. Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL et al. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: Longitudinal dissociation. Circ Arrhythm Electrophysiol 2010;3:606-15.
75. Eckstein J, Maesen B, Linz D, Zeemering S, van Hunnik A, Verheule S et al. Time course and mechanisms of endo-epicardial electrical dissociation during atrial fibrillation in the goat. Cardiovasc Res 2011;89:816-24.
76. Verheule S, Tuyls E, van Hunnik A, Kuiper M, Schotten U, Allessie M. Fibrillatory conduction in the atrial free walls of goats in persistent and permanent atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:590-9.
77. Eckstein J, Verheule S, de Groot NM, Allessie M, Schotten U. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria. Prog Biophys Mol Biol 2008; 97:435-51.
78. Schotten U, Maesen B, Zeemering S. The need for standardization of time-And frequency-domain analysis of body surface electrocardiograms for assessment of the atrial fibrillation substrate. Europace 2012;14:1072-5.
79. Kappenberger L.Anewlook at atrial fibrillation: Lessons learned from drugs, pacing, and ablation theapies-the René Laennec Lecture on Clinical Cardiology of the ESC 2012. Eur Heart J 2013; in press.
80. Ramanathan C, GhanemRN, Jia P, Ryu K, RudyY. Noninvasive electrocardiographic imaging for cardiac electrophysiology and arrhythmia. Nat Med 2004;10:422-8.
81. Guillem MS, Climent AM, Castells F, Husser D, Millet J, Arya A et al. Noninvasive mapping of human atrial fibrillation. J Cardiovasc Electrophysiol 2009;20:507-13.
82. Cuculich PS,Wang Y, Lindsay BD, Faddis MN, Schuessler RB, Damiano RJ Jr. et al. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation 2010;122:1364-72.
83. Vermeer SE, Longstreth WT Jr., Koudstaal PJ. Silent brain infarcts: A systematic review. Lancet Neurol 2007;6:611-9.
84. Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ et al. Prevalence and correlates of silent cerebral infarcts in the Framingham Offspring Study. Stroke 2008;39:2929-35.
85. Hara M, Ooie T, Yufu K, Tsunematsu Y, Kusakabe T, Ooga M et al. Silent cortical strokes associated with atrial fibrillation. Clin Cardiol 1995;18:573-4.
86. Kobayashi A, Iguchi M, Shimizu S, Uchiyama S. Silent cerebral infarcts and cerebral white matter lesions in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis 2012;21:310-7.
87. Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke 2012;43:265-70.
88. Medi C, Evered L, Silbert B, The A, Halloran K, Morton J et al. Subtle postprocedural cognitive dysfunction following atrial fibrillation ablation. J Am Coll Cardiol 2013; in press.
89. Haeusler KG, Koch L, Herm J, Kopp UA, Heuschmann PU, Endres M et al. 3 Tesla MRI-detected brain lesions after pulmonary vein isolation for atrial fibrillation: Results of the MACPAF Study. J Cardiovasc Electrophysiol 2013;24:14-21.
90. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline.NEngl J Med 2003;348: 1215-22.
91. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-Analysis. BMJ 2010; 341:c3666.
92. Silent brain infarction in nonrheumatic atrial fibrillation. EAFT Study Group. European Atrial Fibrillation Trial. Neurology 1996;46:159-65.
93. Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: Results of the ONTARGET and TRANSCEND Studies. CMAJ 2012;184:E329-36.
94. Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda BrantesMet al. Atrial fibrillation and the risk of incident dementia: A meta-Analysis. Heart Rhythm 2012;9: 1761-8.
95. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: A systematic review and meta-Analysis. Neurology 2011;76:914-22.
96. de Leeuw FE, de Groot JC, Oudkerk M, Kors JA, Hofman A, van Gijn J et al. Atrial fibrillation and the risk of cerebral white matter lesions. Neurology 2000;54: 1795-801.
97. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P et al. Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-35.
98. Haines DE, StewartMT, Barka ND, Kirchhof N, Lentz LR, ReinkingNMet al. Microembolism and catheter ablation II: Effects of cerebral microemboli injection in a canine model. Circ Arrhythm Electrophysiol 2013;6:23-30.
99. Schmidt H, Zeginigg M, Wiltgen M, Freudenberger P, Petrovic K, Cavalieri M et al. Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain 2011;134: 3384-97.
100. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) Study Groups. Neurology 1999;53:1319-27.
101. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S et al. Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol 2009;8:165-74.
102. Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, Schmidt R et al. Histopathologic analysis of foci of signal loss on gradient-echo T2-weighted MR images in patients with spontaneous intracerebral hemorrhage: Evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637-42.
103. Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Sorimachi T et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: A systematic review of published and unpublished studies. Stroke 2010;41: 1222-8.
104. Stehling C,WerschingH, Kloska SP, Kirchhof P, Ring J, Nassenstein I et al. Detection of asymptomatic cerebral microbleeds: A comparative study at 1.5 and 3.0 T. Acad Radiol 2008;15:895-900.
105. Cordonnier C, Al-Shahi Salman R,Wardlaw J. Spontaneous brain microbleeds: Systematic review, subgroup analyses and standards for study design and reporting. Brain 2007;130:1988-2003.
106. Charidimou A, Kakar P, Fox Z,Werring DJ. Cerebral microbleeds and recurrent stroke risk: Systematic review and meta-Analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke 2013; in press.
107. HolmesDR, ReddyVY, Turi ZG, Doshi SK, Sievert H, BuchbinderMet al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009;374:534-42.
108. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: Results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) Clinical Trial and the Continued Access Registry. Circulation 2013; in press.
109. Charidimou A, Shakeshaft C,Werring DJ. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-Associated intracerebral hemorrhage risk. Front Neurol 2012;3:133.
110. Waggoner AD, Adyanthaya AV, Quinones MA, Alexander JK. Left atrial enlargement. echocardiographic assessment of electrocardiographic criteria. Circulation 1976;54:553-7.
111. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24.
112. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301-7.
113. Truelsen T, Lindenstrom E, Boysen G. Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study. Stroke 1994;25:802-7.
114. Aronow WS, Ahn C, Kronzon I, Gutstein H. Association of left ventricular hypertrophy and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 2,384 older persons. Am J Cardiol 1999;84:468-9, A9.
115. Tsang TS, Barnes ME, Gersh BJ, TakemotoY, Rosales AG, BaileyKR et al. Prediction of risk for first age-related cardiovascular events in an elderly population: The incremental value of echocardiography. J Am Coll Cardiol 2003;42:1199-205.
116. Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ,Wolf PA et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994;272:33-6.
117. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
118. BoydAC, McKayT, Nasibi S, RichardsDA, Thomas L. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. Eur Heart J Cardiovasc Imaging 2013;14:269-75.
119. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158: 1316-20.
120. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
121. Lip GY, Rasmussen LH, Skjoth F, Overvad K, Larsen TB. Stroke and mortality in patients with incident heart failure: The Diet, Cancer and Health (DCH) cohort study. BMJ Open 2012;2.
122. Jang SJ, Kim MS, Park HJ, Han S, Kang DH, Song JK et al. Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart 2013;99:17-21.
123. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: The Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012;14:295-301.
124. Epstein FH. MRI of left ventricular function. J Nucl Cardiol 2007;14:729-44.
125. Gorcsan J III, Tanaka H. Echocardiographic assessment of myocardial strain. J Am Coll Cardiol 2011;58:1401-13.
126. Benjamin EJ, D'Agostino RB, Belanger AJ,Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995;92:835-41.
127. Tsang TS, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR et al. Prediction of cardiovascular outcomeswith left atrial size: Is volume superior to area or diameter? J Am Coll Cardiol 2006;47:1018-23.
128. Orlando JR, van Herick R, Aronow WS, Olson HG. Hemodynamics and echocardiograms before and after cardioversion of atrial fibrillation to normal sinus rhythm. Chest 1979;76:521-6.
129. Bartall H, Desser KB, Benchimol A, Massey BJ. Assessment of echocardiographic left atrial enlargement in patients with atrial fibrillation. An electrovectorcardiographic study. J Electrocardiol 1978;11:269-72.
130. Mor-AviV, Yodwut C, Jenkins C, Kuhl H, Nesser HJ, MarwickTHet al. Real-time3D echocardiographic quantification of left atrial volume: Multicenter study for validation with CMR. JACC Cardiovasc Imaging 2012;5:769-77.
131. Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol 2012;60:531-8.
132. To AC, Flamm SD, Marwick TH, Klein AL. Clinical utility of multimodality LA imaging: Assessment of size, function, and structure. JACC Cardiovasc Imaging 2011;4:788-98.
133. Tops LF, Schalij MJ, Bax JJ. Imaging and atrial fibrillation: The role of multimodality imaging in patient evaluation and management of atrial fibrillation. Eur Heart J 2010;31:542-51.
134. Everett THt, Wilson EE, Olgin JE. Effects of atrial fibrillation substrate and spatiotemporal organization on atrial defibrillation thresholds. Heart Rhythm 2007;4: 1048-56.
135. Therkelsen SK, Groenning BA, Svendsen JH, Jensen GB. Atrial and ventricular volume and function evaluated by magnetic resonance imaging in patients with persistent atrial fibrillation before and after cardioversion. Am J Cardiol 2006;97: 1213-9.
136. Marsan NA, Tops LF, Holman ER, Van de Veire NR, Zeppenfeld K, Boersma E et al. Comparison of left atrial volumes and function by real-time three-dimensional echocardiography in patients having catheter ablation for atrial fibrillation with persistence of sinus rhythm versus recurrent atrial fibrillation three months later. Am J Cardiol 2008;102:847-53.
137. Kuppahally SS, Akoum N, Badger TJ, Burgon NS, Haslam T, Kholmovski E et al. Echocardiographic left atrial reverse remodeling after catheter ablation of atrial fibrillation is predicted by preablation delayed enhancement of left atrium by magnetic resonance imaging. Am Heart J 2010;160:877-84.
138. Gosselink AT, Crijns HJ, Hamer HP, Hillege H, Lie KI. Changes in left and right atrial size after cardioversion of atrial fibrillation: Role of mitral valve disease. J Am Coll Cardiol 1993;22:1666-72.
139. Gerdts E,Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K et al. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: Losartan intervention for endpoint reduction in hypertension trial. Hypertension 2007;49:311-6.
140. Gottdiener JS, Reda DJ, Williams DW, Materson BJ, Cushman W, Anderson RJ. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: Comparison of six antihypertensive agents. Circulation 1998;98: 140-8.
141. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 1995;25:1155-60.
142. Bang CN, Dalsgaard M, Greve AM, Kober L, Gohlke-Baerwolf C, Ray S et al. Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: The simvastatin and ezetimibe in aortic stenosis study. Int J Cardiol 2013; in press.
143. Park JH, Joung B, Son NH, Shim JM, Lee MH, Hwang C et al. The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation. Europace 2011;13:1541-9.
144. Tops LF, Delgado V, Bertini M, Marsan NA, Den UijlDW, Trines SA et al. Left atrial strain predicts reverse remodeling after catheter ablation for atrial fibrillation. J Am Coll Cardiol 2011;57:324-31.
145. Weijs B, de Vos CB, Tieleman RG, Pisters R, Cheriex EC, PrinsMHet al. Clinical and echocardiographic correlates of intra-Atrial conduction delay. Europace 2011;13: 1681-7.
146. De Vos CB,Weijs B, Crijns HJ, Cheriex EC, Palmans A, Habets J et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart 2009;95: 835-40.
147. Bertini M, Borleffs CJ, DelgadoV,NgAC, Piers SR, ShanksMet al. Prediction of atrial fibrillation in patients with an implantable cardioverter-defibrillator and heart failure. Eur J Heart Fail 2010;12:1101-10.
148. Oakes RS, Badger TJ, Kholmovski EG, AkoumN, BurgonNS, FishEN et al. Detection and quantification of left atrial structural remodeling with delayed-enhancementmagnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119: 1758-67.
149. Mahnkopf C, Badger TJ, Burgon NS, DaccarettM, Haslam TS, BadgerCTet al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: Implications for disease progression and response to catheter ablation. Heart Rhythm 2010;7:1475-81.
150. AkkayaM, HiguchiK,Koopmann M, Damal K, Burgon NS, Kholmovski Eet al. Higher degree of left atrial structural remodeling in patients with atrial fibrillation and left ventricular systolic dysfunction. J Cardiovasc Electrophysiol 2013; in press.
151. Akoum N, McGann C, Vergara G, Badger T, Ranjan R, Mahnkopf C et al. Atrial fibrosis quantified using late gadolinium enhancement MRI is associated with sinus node dysfunction requiring pacemaker implant. J Cardiovasc Electrophysiol 2012; 23:44-50.
152. Peters DC, Wylie JV, Hauser TH, Kissinger KV, Botnar RM, Essebag V et al. Detection of pulmonary vein and left atrial scar after catheter ablation with threedimensional navigator-gated delayed enhancement MR imaging: Initial experience. Radiology 2007;243:690-5.
153. Ozgun M, Maintz D, Bunck AC, Monnig G, Eckardt L,Wasmer K et al. Right atrial scar detection after catheter ablation: Comparison of 2Dand high spatial resolution 3D-late enhancement magnetic resonance imaging. Acad Radiol 2011;18:488-94.
154. Badger TJ, Daccarett M, AkoumNW, Adjei-Poku YA, Burgon NS, Haslam TS et al. Evaluation of left atrial lesions after initial and repeat atrial fibrillation ablation: Lessons learned from delayed-enhancement MRI in repeat ablation procedures. Circ Arrhythm Electrophysiol 2010;3:249-59.
155. Lip GY. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC Guidelines on Atrial Fibrillation: Acommentary. J Thromb Haemost 2013;11: 615-26.
156. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373:155-66.
157. LipGY, Lip PL, Zarifis J,Watson RD, Bareford D, LoweGDet al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996;94:425-31.
158. Wannamethee SG, Whincup PH, Lennon L, Rumley A, Lowe GD. Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men. Stroke 2012;43:1206-11.
159. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chornic atrial fibrillation during oral coagulant therapy. Thromb Haemost 2003; in press (please insert the page numbers here).
160. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006; 109:59-65.
161. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107: 3141-5.
162. Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2013; in press.
163. SadanagaT, Sadanaga M,Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010;55:2225-31.
164. Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H et al. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 2007;28: 2217-22.
165. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012;125:1605-16.
166. Hijazi Z, Oldgren J, Siegbahn A, Granger CB,Wallentin L. Biomarkers in atrial fibrillation: A clinical review. Eur Heart J 2013; in press.
167. LongstrethWTJr., Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R et al. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke 2013;44:714-9.
168. Roldan V, Marin F, Diaz J, Gallego P, Jover E, RomeraMet al. High sensitivity cardiac troponinTand interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012;10:1500-7.
169. Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters GB, Thorgeirsson G et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 2009;41:876-8.
170. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008.
171. Van Spall HG,Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: An analysis of patients receiving warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Circulation 2012;126:2309-16.
172. Weng YC, Sonni A, Labelle-Dumais C, de Leau M, Kauffman WB, Jeanne M et al. COL4A1mutations in patients with sporadic late-onset intracerebral hemorrhage. Ann Neurol 2012;71:470-7.
173. Brouwers HB, Biffi A, Ayres AM, Schwab K, Cortellini L, Romero JMet al. Apolipoprotein E genotype predicts hematoma expansion in lobar intracerebral hemorrhage. Stroke 2012;43:1490-5.
174. Biffi A, Shulman JM, Jagiella JM, Cortellini L, Ayres AM, Schwab K et al. Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 2012;78: 334-41.
175. Exploitingcommon genetic variation to make anticoagulation safer. Stroke 2009;40: S64-6.
176. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367: 625-35.
177. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 2009;119:1363-9.
178. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, HannaMet al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: Insights from the ARISTOTLE Trial. Eur Heart J 2012;33: 2821-30.
179. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y,GoAS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 2013;127:224-32.
180. CammAJ, Savelieva I. 'R' for 'renal' and for 'risk': Refining risk stratification for stroke in atrial fibrillation. Circulation 2013;127:169-71.
181. Roldan V, Marin F, Manzano-Fernandez S, Fernandez H, Gallego P, Valdes M et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109.
182. Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM et al. Renal impairment and ischaemic stroke risk assessment in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013; in press.
183. Latini R, Masson S, Pirelli S, Barlera S, Pulitano G, Carbonieri E et al. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: Data from the GISSI-Atrial Fibrillation Trial. J Intern Med 2011;269:160-71.
184. Hussein AA, Saliba WI, Martin DO, Shadman M, Kanj M, Bhargava M et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation 2011;123:2077-82.
185. Malouf JF, Kanagala R, Al Atawi FO, Rosales AG, Davison DE, Murali NS et al. High sensitivity C-reactive protein: A novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005;46:1284-7.
186. Lellouche N, Berthier R, Mekontso-Dessap A, Braconnier F, Monin JL, Duval AM et al. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol 2005;95: 1380-2.
187. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010;121:200-7.
188. den Uijl DW, Delgado V, Tops LF, Ng AC, Boersma E, Trines SA et al. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J 2011;161:197-203.
189. Kojima S, FujiiT, Ohe T, KarakawaS, Iida T, HirataYet al. Physiologic changes during supraventricular tachycardia and release of atrial natriuretic peptide. Am J Cardiol 1988;62:576-9.
190. Tsai RC, Yamaji T, Ishibashi M, Takaku F, Pang SC, Yeh SJ et al. Atrial natriuretic peptide during supraventricular tachycardia and relation to hemodynamic changes and renal function. Am J Cardiol 1988;61:1260-4.
191. ArakawaM, Miwa H, Noda T, Ito Y, Kambara K, Kagawa K et al. Alternations in atrial natriuretic peptide release afterDCcardioversion of non-valvular chronic atrial fibrillation. Eur Heart J 1995;16:977-85.
192. Lechleitner P, Genser N, Hauptlorenz S, Putensen C, Mitterschiffthaler G, Artner-Dworzak E et al. [Values of atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) in cardioversion]. Z Kardiol 1991;80:574-9.
193. Sacher F, Corcuff JB, Schraub P, Le Bouffos V, Georges A, Jones SO et al. Chronic atrial fibrillation ablation impact on endocrine and mechanical cardiac functions. Eur Heart J 2008;29:1290-5.
194. Okumura Y,Watanabe I, Nakai T, Ohkubo K, Kofune T, Kofune M et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2011;22:987-93.
195. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: Biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 2008;52:211-5.
196. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008;94:200-4.
197. RichterB, Gwechenberger M, Socas A,Zorn G, Albinni S, MarxMet al. Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. Int J Cardiol 2011;152:231-6.
198. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16:470-4.
199. Ehret GB, Munroe PB, Rice KM, BochudM, JohnsonAD, Chasman DI et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478:103-9.
200. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004;110:2313-9.
201. Liakopoulos OJ, KuhnEW, Slottosch I,Wassmer G,Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012;4: CD008493.
202. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-Analysis. J Am Coll Cardiol 2007;49:1642-8.
203. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L et al. Relation of C-reactive protein to long-termrisk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007;99:1421-4.
204. Richter B, Gwechenberger M, Socas A, Zorn G, Albinni S, MarxMet al. Markers of oxidative stress after ablation of atrial fibrillation are associated with inflammation, delivered radiofrequency energy and early recurrence of atrial fibrillation. Clin Res Cardiol 2012;101:217-25.
205. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A et al. Myocardial redox state predicts in-hospital clinical outcomeafter cardiac surgery effects of short-termpre-operative statin treatment. J Am Coll Cardiol 2012;59:60-70.
206. Wu JH, Lemaitre RN, King IB, Song X, Sacks FM, Rimm EB et al. Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: The cardiovascular health study. Circulation 2012;125: 1084-93.
207. Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ et al. Fish oil and postoperative atrial fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA 2012;308: 2001-11.
208. Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: A randomized, double-blind, placebocontrolled clinical trial. Circ Arrhythm Electrophysiol 2009;3:46-53.
209. Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010;12:356-63.
210. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellanWet al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011;4:26-32.
211. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S et al. Comprehensive risk reduction in patients with atrial fibrillation:emerging diagnostic and therapeutic options-A report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association Consensus Conference. Europace 2012;14:8-27.
212. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV et al. Meta-Analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012;44:670-5.
213. Virani SS, Brautbar A, Lee VV, Elayda M, Sami S, Nambi V et al. Usefulness of single nucleotide polymorphism in chromosome 4q25 to predict in-hospital and longterm development of atrial fibrillation and survival in patients undergoing coronary artery bypass grafting. Am J Cardiol 2011;107:1504-9.
214. Body SC, Collard CD, Shernan SK, Fox AA, Liu KY, RitchieMDet al. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet 2009;2:499-506.
215. Parvez B, Vaglio J, Rowan S, Muhammad R, Kucera G, Stubblefield Tet al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2013; in press.
216. Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2010;55:747-53.
217. Kahr PC, Piccini I, Fabritz L, Greber B, Scholer H, Scheld HH et al. Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue. PLoS ONE 2011;6:e26389.
218. Hsu J, Hanna P, Van Wagoner DR, Barnard J, Serre D, Chung MK et al. Whole genome expression differences in human left and right atria ascertained by RNA sequencing. Circ Cardiovasc Genet 2012;5:327-35.
219. Parvez B,Chopra N, RowanS, Vaglio JC, Muhammad R, RodenDMet al.Acommon beta1-Adrenergic receptor polymorphism predicts favorable response to ratecontrol therapy in atrial fibrillation. J Am Coll Cardiol 2012;59:49-56.